AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27938399 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 738
Study 27938399 — intervention group
Group type: EXPERIMENTAL
Intervention: WC
Number of subjects: 738
Study 27938399 — intervention group
Group type: EXPERIMENTAL
Intervention: WHtR
Number of subjects: 738
Study 27938399 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 738
Study 27938399 — intervention group
Group type: EXPERIMENTAL
Intervention: Central obesity
Number of subjects: 738
Study 27938896 — intervention group
Group type: EXPERIMENTAL
Intervention: Home administration of intranasal LAIV by parents
Number of subjects: 41
Study 27938897 — intervention group
Group type: COMPARATOR
Intervention: Naloxegol
Number of subjects: 1337
Study 27938911 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (3 mg/kg) infusion for 10 minutes
Number of subjects: 48
Study 27938911 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sedation)
Number of subjects: 48
Study 27939059 — intervention group
Group type: EXPERIMENTAL
Intervention: Nusinersen 12 mg dose
Number of subjects: 20
Study 27939380 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study 27939380 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 27939400 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg intravenous every 21 days until progression
Number of subjects: 123
Study 27940595 — intervention group
Group type: EXPERIMENTAL
Intervention: Giant cell arteritis patients with prevalent stroke
Number of subjects: 433
Study 27940595 — intervention group
Group type: EXPERIMENTAL
Intervention: Giant cell arteritis patients with peripheral vascular disease
Number of subjects: 433
Study 27940636 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution ultrasonography of peripheral and spinal nerves
Number of subjects: 205
Study 27940685 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal maternal iron deficiency (ID)
Number of subjects: 636
Study 27940685 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal ID anemia (IDA) at delivery
Number of subjects: 636
Study 27940685 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation during pregnancy
Number of subjects: 636
Study 27940696 — intervention group
Group type: EXPERIMENTAL
Intervention: NIAAA SG
Number of subjects: 1573
Study 27940696 — intervention group
Group type: EXPERIMENTAL
Intervention: CRAFFT
Number of subjects: 1573
Study 27940696 — intervention group
Group type: EXPERIMENTAL
Intervention: PESQ-PS
Number of subjects: 1573
Study 27940696 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Use Disorders Identification Test
Number of subjects: 1573
Study 27940696 — intervention group
Group type: EXPERIMENTAL
Intervention: PESQ-PS and CRAFFT
Number of subjects: 1573
Study 27941019 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 1388
Study 27941066 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration during PCI
Number of subjects: 180306
Study 27941066 — intervention group
Group type: COMPARATOR
Intervention: PCI alone
Number of subjects: 180306
Study 27941066 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration during PCI (high thrombus burden)
Number of subjects: 180306
Study 27941066 — intervention group
Group type: COMPARATOR
Intervention: PCI alone (high thrombus burden)
Number of subjects: 180306
Study 27941217 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated RR-interval series calculated with the AIT Multi-Lead ECGsolver
Number of subjects: 339
Study 27941217 — intervention group
Group type: COMPARATOR
Intervention: Manually reviewed reference RR-time series
Number of subjects: 339
Study 27942587 — intervention group
Group type: EXPERIMENTAL
Intervention: Chorioretinal thinning assessment in chronic kidney disease patients
Number of subjects: 0
Study 27942917 — intervention group
Group type: EXPERIMENTAL
Intervention: LJM716 (40 mg/kg, intravenously, once weekly in 28-day cycles)
Number of subjects: 12
Study 27943107 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegLira once daily
Number of subjects: 438
Study 27943107 — intervention group
Group type: COMPARATOR
Intervention: Unchanged GLP-1RA therapy
Number of subjects: 438
Study 27955679 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutemetamol F 18 injection
Number of subjects: 0
Study 27955681 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymeric sealant
Number of subjects: 112
Study 27955684 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab (840 mg loading, 420 mg maintenance doses) and Trastuzumab (8 mg/kg loading, 6 mg/kg maintenance doses), followed by Vinorelbine (25 mg/m2)
Number of subjects: 106
Study 27955875 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing child and family education and self-management support
Number of subjects: 13
Study 27955875 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental control and housing resources
Number of subjects: 13
Study 27955875 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkages to smoking cessation programs
Number of subjects: 13
Study 27955875 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial support
Number of subjects: 13
Study 27956157 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg once daily until progression or unacceptable toxicity
Number of subjects: 31
Study 27956377 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus guaranteed incentives (Can $1 per day step goal met)
Number of subjects: 100
Study 27956377 — intervention group
Group type: COMPARATOR
Intervention: Standard care (wellness program, accelerometer)
Number of subjects: 100
Study 27956421 — intervention group
Group type: EXPERIMENTAL
Intervention: Miltefosine (Impavido) at a nominal dose of 2.5 mg/kg/day for 28 days
Number of subjects: 60
Study 27956671 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine flow rate during CPB
Number of subjects: 503
Study 27956671 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine flow rate <1.5 ml/kg
Number of subjects: 503
Study 27957340 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Flexible Bronchoscopy with Multiplanar CT Planning
Number of subjects: 0
Study 27958229 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of sepsis
Number of subjects: 0
Study 27958229 — intervention group
Group type: EXPERIMENTAL
Intervention: Etiology of sepsis
Number of subjects: 0
Study 27958229 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent risk factors for increased mortality from sepsis
Number of subjects: 0
Study 27959685 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened donations (n=75,331)
Number of subjects: 89153
Study 27959685 — intervention group
Group type: COMPARATOR
Intervention: Unscreened donations (n=253,031)
Number of subjects: 89153
Study 27959707 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe acute kidney injury (stage 2 or 3)
Number of subjects: 4683
Study 27959707 — intervention group
Group type: COMPARATOR
Intervention: No severe acute kidney injury
Number of subjects: 4683
Study 27959707 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe acute kidney injury
Number of subjects: 4683
Study 27959707 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute kidney injury severity
Number of subjects: 4683
Study 27959728 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC01 (bNAb targeting HIV CD4-binding site)
Number of subjects: 24
Study 27959731 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine (20 mg/m²/day for 10 consecutive days in monthly cycles)
Number of subjects: 116
Study 27959736 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully implanted brain-computer interface with subdural electrodes over the motor cortex and a subcutaneously placed transmitter.
Number of subjects: 1
Study 27959736 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain-computer interface
Number of subjects: 1
Study 27964737 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic Decision Support Software (DDSS)
Number of subjects: 26
Study 27964867 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioimmunotherapy (anti-CD22)
Number of subjects: 71
Study 27964869 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary methadone treatment in VTCs
Number of subjects: 184
Study 27964869 — intervention group
Group type: COMPARATOR
Intervention: Compulsory drug detention centres (CDDCs)
Number of subjects: 184
Study 27965253 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based Guided Self-Determination (GSD) intervention
Number of subjects: 0
Study 27965258 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoassays performed with blood samples from patients
Number of subjects: 3
Study 27965782 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated intervention based on the PARiHS framework
Number of subjects: 10
Study 27965782 — intervention group
Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 10
Study 27965789 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml 0.5% ropivacaine
Number of subjects: 30
Study 27965789 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml 0.33% ropivacaine
Number of subjects: 30
Study 27965789 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 ml 0.25% ropivacaine
Number of subjects: 30
Study 27965798 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics administered to mechanically ventilated critically ill patients
Number of subjects: 0
Study 27965798 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0
Study 27965798 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 27965808 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component physiotherapist-led intervention including a 40-min education module, guided goal-setting, action planning, wristband activity tracker, and weekly follow-up phone calls.
Number of subjects: 36
Study 27965808 — intervention group
Group type: COMPARATOR
Intervention: Delayed-intervention group (5-week delay before intervention).
Number of subjects: 36
Study 27965808 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-intervention group (4-week intervention).
Number of subjects: 36
Study 27965808 — intervention group
Group type: COMPARATOR
Intervention: N/A (baseline measures).
Number of subjects: 36
Study 27965809 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerin suppository (250 mg)
Number of subjects: 30
Study 27965809 — intervention group
Group type: COMPARATOR
Intervention: Placebo (250 mg glycerin suppository placed in the diaper)
Number of subjects: 30
Study 27965816 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic pathways (16 possible combinations of diagnostic tools)
Number of subjects: 200
Study 27965816 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collection on clinical history, diagnostic path, treatment, and urine culture
Number of subjects: 200
Study 27965817 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural activation (BA) added to usual care
Number of subjects: 0
Study 27965817 — intervention group
Group type: COMPARATOR
Intervention: Depression support group with usual care
Number of subjects: 0
Study 27965841 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation (BA) group therapy
Number of subjects: 0
Study 27965843 — intervention group
Group type: EXPERIMENTAL
Intervention: Aging, Community and Health-Community Partnership Program (6-month interprofessional, nurse-led program)
Number of subjects: 51
Study 27965843 — intervention group
Group type: EXPERIMENTAL
Intervention: Aging, Community and Health-Community Partnership Program
Number of subjects: 51
Study 27965842 — intervention group
Group type: EXPERIMENTAL
Intervention: HN-STAR (Head and Neck Survivorship Tool: Assessment and Recommendations), an electronic platform for personalized care in cancer survivorship clinics.
Number of subjects: 0
Study 27965842 — intervention group
Group type: EXPERIMENTAL
Intervention: HN-STAR
Number of subjects: 0
Study 27965845 — intervention group
Group type: EXPERIMENTAL
Intervention: General health education condition
Number of subjects: 40
Study 27965845 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy eating physical activity skills condition
Number of subjects: 40
Study 27965856 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 0
Study 27965856 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 0
Study 27965861 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AET) program, 12-week duration, supervised, progressive intensity, 2 sessions per week, 45 minutes each.
Number of subjects: 0
Study 27965866 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural progesterone (Prometrium, 200 mg) vaginally every night from gestational week 16 to 36
Number of subjects: 40
Study 27965866 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 40
Study 27965873 — intervention group
Group type: EXPERIMENTAL
Intervention: My MFG (mobile health application)
Number of subjects: 0
Study 27965873 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 27965885 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (two 30-45 min sessions per week for three consecutive weeks, in addition to care as usual)
Number of subjects: 52
Study 27965885 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 52
Study 27966809 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxypeptidase G2 (CPDG) administered to 47 children
Number of subjects: 1286
Study 27966809 — intervention group
Group type: COMPARATOR
Intervention: High-dose methotrexate (5 g/m2)
Number of subjects: 1286
Study 27967215 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular triamcinolone acetonide (TA)
Number of subjects: 526
Study 27967215 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 526
Study 27973930 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilator support (invasive or noninvasive)
Number of subjects: 78
Study 27974047 — intervention group
Group type: EXPERIMENTAL
Intervention: TRK inhibition
Number of subjects: 186
Study 27974047 — intervention group
Group type: EXPERIMENTAL
Intervention: FGFR1 gene fusions (FGFR1-HOOK3, FGFR1-TACC1)
Number of subjects: 186
Study 27974047 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive genomic profiling (CGP)
Number of subjects: 186
Study 27974310 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum potassium (high-normal)
Number of subjects: 2157
Study 27974310 — intervention group
Group type: COMPARATOR
Intervention: Serum potassium (low-normal)
Number of subjects: 2157
Study 27974310 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone (normal <9 ng/dL)
Number of subjects: 2157
Study 27974310 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone (high-normal ≥9 ng/dL)
Number of subjects: 2157
Study 27974310 — intervention group
Group type: COMPARATOR
Intervention: Dietary potassium
Number of subjects: 2157
Study 27974310 — intervention group
Group type: COMPARATOR
Intervention: Urinary potassium
Number of subjects: 2157
Study 27974370 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scanning for all anticoagulated patients with head injury
Number of subjects: 3566
Study 27974370 — intervention group
Group type: COMPARATOR
Intervention: Selective CT use based on guidelines
Number of subjects: 3566
Study 27974525 — intervention group
Group type: EXPERIMENTAL
Intervention: 16S rRNA gene PCR for rapid exclusion of VAP
Number of subjects: 0
Study 27974525 — intervention group
Group type: COMPARATOR
Intervention: Microbiological cultures
Number of subjects: 0
Study 27974691 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided Nd:YAG laser ablation
Number of subjects: 4
Study 27974691 — intervention group
Group type: COMPARATOR
Intervention: Literature review of thermal ablation
Number of subjects: 4
Study 27974888 — intervention group
Group type: EXPERIMENTAL
Intervention: Telekit System from the Danish TeleCare North Trial
Number of subjects: 0
Study 27977002 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telemonitoring
Number of subjects: 900
Study 27977390 — intervention group
Group type: EXPERIMENTAL
Intervention: WAPPS-Hemo Web-based calculator for individualized pharmacokinetic estimation
Number of subjects: 878
Study 27977390 — intervention group
Group type: EXPERIMENTAL
Intervention: Population pharmacokinetics models
Number of subjects: 878
Study 27977934 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 5598
Study 27977934 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 5598
Study 27977934 — intervention group
Group type: COMPARATOR
Intervention: Non-canagliflozin treatments (placebo, sitagliptin, glimepiride)
Number of subjects: 5598
Study 27977934 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 5598
Study 27978559 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT-Leakage algorithm
Number of subjects: 48
Study 27978559 — intervention group
Group type: COMPARATOR
Intervention: Control group of 25 healthy eyes
Number of subjects: 48
Study 27978569 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-vision devices with therapy
Number of subjects: 323
Study 27978569 — intervention group
Group type: COMPARATOR
Intervention: Low-vision devices without therapy
Number of subjects: 323
Study 27978840 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotype 1: mild, good lung function, early onset, low-inflammatory, predominantly Type-2
Number of subjects: 156
Study 27978840 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotype 2: moderate, hyper-responsive, eosinophilic, moderate asthma control, mild airflow obstruction, predominant Type-2 inflammation
Number of subjects: 156
Study 27978840 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotype 3: mixed severity, predominantly fixed obstructive, non-eosinophilic and neutrophilic, moderate asthma control, low Type-2 inflammation
Number of subjects: 156
Study 27978840 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotype 4: severe uncontrolled, severe reversible obstruction, mixed granulocytic, moderate Type-2 inflammation
Number of subjects: 156
Study 27978840 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster classification probabilities derived from ADEPT data
Number of subjects: 156
Study 27979025 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopy patch tests (APTs) with locally lyophilized food allergens
Number of subjects: 56
Study 27979025 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick tests (SPTs) with locally lyophilized food allergens
Number of subjects: 56
Study 27979025 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopy patch tests (APTs) for D. farinae, D. pteronyssinus, and American cockroach
Number of subjects: 56
Study 27979025 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick tests (SPTs) for D. farinae, D. pteronyssinus, and American cockroach
Number of subjects: 56
Study 27979791 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to Diabetes Adherence in adolescent scale
Number of subjects: 380
Study 27979791 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Efficacy for Diabetes Self-Management measure
Number of subjects: 380
Study 27979791 — intervention group
Group type: EXPERIMENTAL
Intervention: World Health Organization-5 Well-Being Index
Number of subjects: 380
Study 27979791 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-ended questions and open-ended questions
Number of subjects: 380
Study 27980409 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone 40 mg/d
Number of subjects: 2218
Study 27980409 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone 20-40 mg/d
Number of subjects: 2218
Study 27980409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2218
Study 27980462 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 30 mg QD
Number of subjects: 1326
Study 27980462 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 20 mg BID
Number of subjects: 1326
Study 27980605 — intervention group
Group type: EXPERIMENTAL
Intervention: Early neonatal food (ENF) feeding
Number of subjects: 25286
Study 27980605 — intervention group
Group type: COMPARATOR
Intervention: Control (no ENF feeding)
Number of subjects: 25286
Study 27980771 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurobiologically based five-day treatment for anorexia nervosa
Number of subjects: 37
Study 27980782 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole genome prediction methods
Number of subjects: 832
Study 27980782 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole genome prediction methods with additional demographic covariates
Number of subjects: 832
Study 27980782 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole genome prediction methods with SNP-prioritization
Number of subjects: 832
Study 27980787 — intervention group
Group type: EXPERIMENTAL
Intervention: Group training program based on cognitive-behavioral principles and skills from Dialectical Behavior Therapy (DBT)
Number of subjects: 0
Study 27980787 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 27980877 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprachoroidal injection of 4-mg triamcinolone acetonide (TA) in 100 μL
Number of subjects: 9
Study 27981865 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarucizumab
Number of subjects: 90
Study 27982165 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (zinc)
Number of subjects: 14
Study 27982165 — intervention group
Group type: COMPARATOR
Intervention: Nutritional evaluations (anthropometric measurements)
Number of subjects: 14
Study 27982165 — intervention group
Group type: COMPARATOR
Intervention: Serum albumin and zinc measurements
Number of subjects: 14
Study 27982165 — intervention group
Group type: COMPARATOR
Intervention: Lymphocyte count on the 1st day
Number of subjects: 14
Study 27982165 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocyte counts and zinc concentrations
Number of subjects: 14
Study 27984247 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Ultrasound-Guided Short-Axis Needle Tip Navigation Technique
Number of subjects: 100
Study 27986363 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus bevacizumab
Number of subjects: 205
Study 27986651 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab (150 mg, 5 doses, 2 weeks apart)
Number of subjects: 18
Study 27986651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18